Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment

2. září 2026 aktualizováno: Hangzhou Gensciences Biopharmaceutical Co., Ltd.

A Single-arm, Open-label, Multicenter Phase III Clinical Study Evaluating the Efficacy, Safety, and Immunogenicity of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-demand Treatment in Patients With Severe Hemophilia A (Adults and Adolescents) .

The indication for this product is to control bleeding in patients with hemophilia A (congenital deficiency of factor VIII).

The primary objective:

Evaluation of the efficacy of recombinant human coagulation factor VIII-Fc fusion protein for injection (FRSW107) as an on-demand treatment in previously treated patients with severe hemophilia A.

Secondary objectives:

Evaluation of the safety and immunogenicity of FRSW107 as an on-demand therapy in previously treated patients with severe hemophilia A.

Evaluate the on-demand treatment's PK profile of FRSW107 in previously treated patients with severe hemophilia A based on population pharmacokinetic (PopPK) methods ; preliminarily investigate the exposure-response (E-R) relationship of FRSW107 on-demand treatment in these patients if data permit.

Přehled studie

Postavení

Aktivní, ne nábor

Intervence / Léčba

Typ studie

Intervenční

Zápis (Odhadovaný)

60

Fáze

  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

      • Fuyang, Čína
        • Fuyang Hospital, Affiliated to Anhui Medical University
      • Fuzhou, Čína
        • Fujian Medical University Union Hospital
      • Ganzhou, Čína
        • Ganzhou People's Hospital
      • Guangzhou, Čína
        • Nanfang Hospital of Southern Medical University
      • Hefei, Čína
        • Anhui Provincial Hospital
      • Huai'an, Čína
        • Huai'an Second People's Hospital
      • Jinan, Čína
        • Jinan Central Hospital
      • Kunming, Čína
        • The Second Affiliated Hospital of Kunming Medical University
      • Nanning, Čína
        • The First Affiliated Hospital of Guangxi Medical University
      • Nantong, Čína
        • Affiliated Hospital of Nantong University
      • Nanyang, Čína
        • The First Affiliated Hospital of Nanyang Medical College
      • Qinghai, Čína
        • Qinghai Provincial People's Hospital
      • Rizhao, Čína
        • Rizhao People's Hospital
      • Shijiazhuang, Čína
        • The Second Hospital of Hebei Medical University
      • Taiyuan, Čína
        • The Second Hospital of Shanxi Medical University
      • Tangshan, Čína
        • North China University of Science and Technology Affiliated Hospital
      • Wenzhou, Čína
        • Wenzhou People's Hospital
      • Wuhan, Čína
        • Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology.
      • Wuxi, Čína
        • Affiliated Hospital of Jiangnan University
      • Xi'an, Čína
        • Xi'an Central Hospital
      • Yangzhou, Čína
        • Subei People's Hospital of Jiangsu province
      • Zhengzhou, Čína
        • Henan Cancer Hospital
      • Zhengzhou, Čína
        • Zhengzhou People's Hospital
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Čína
        • Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dítě
  • Dospělý
  • Starší dospělý

Přijímá zdravé dobrovolníky

Ne

Popis

Inclusive Criteria:

  1. Males aged 12 or younger to 65 years old.
  2. Patients clinically diagnosed with severe hemophilia A, i.e., those confirmed through screening or previous medical records: FⅧ Activity < 1%.
  3. Previous records confirm receipt of any recombinant and/or blood-derived coagulation factor VIII products or cold precipitate products, with a treatment of ≥150 exposure days (EDs ≥150).
  4. The participants have fully understood and been informed of this study, signed the informed consent form, and voluntarily enrolled in the clinical trial. The trial participants and/or their guardians are capable of cooperating with the hemostatic treatment and have the ability to complete all study procedures.

Exclusion Criteria:

  1. Known or suspected allergy to the investigational drug or its excipients, including mouse or hamster proteins;
  2. Hypersensitivity or anaphylaxis after FⅧ or IgG2 injection in the past;
  3. FⅧ inhibitor positive (≥0.6 BU/mL) during the screening period, or have a history of FⅧ inhibitor positive in the past, or a family history of FⅧ inhibitor positive;
  4. Von Willebrand factor (vWF) antigen test results were lower than the lower limit of normal value;
  5. Severe anemia at the screening stage (hemoglobin < 60 g/L);
  6. Platelet count during screening period < 100×109 /L;
  7. Abnormal liver function:

    .Alanine aminotransferase (ALT), or aspartate aminotransferase (AST) >3 times upper limit of normal (ULN); or Serum total bilirubin (TBIL) >1.5x ULN;

  8. Patients with abnormal renal function:

    Creatinine clearance (Ccr) <50 ml/min (according to Cockcroft and Gault formula); or Serum creatinine (Cr) >1.5x ULN;

  9. People with active hepatitis C, that is, hepatitis C virus (HCV) antibody positive and HCV RNA positive; Or anti-treponema pallidum specific antibody (TPHA) positive; Or positive for antibodies against the human immunodeficiency virus (HIV);
  10. Patients with coagulation dysfunction other than hemophilia A;
  11. Have a medical condition that may increase the risk of bleeding;
  12. A history of drug or alcohol abuse;
  13. Have a known mental disorder that may affect trial compliance;
  14. Patients who have received transfusions of blood or blood components within 4 weeks prior to screening;
  15. Participants who had participated in other clinical trials within 1 month before screening;
  16. Use of any anticoagulant or antiplatelet drugs, off-label maximum dose of non-steroidal anti-inflammatory drugs (NSAID) within 7 days prior to screening; Or patients who need to be treated with anticoagulant or antiplatelet drugs or off-label maximum doses of SAID during clinical trials;
  17. Severe cardiovascular and cerebrovascular disease or major thromboembolic events, such as stroke, myocardial infarction, unstable angina, congestive heart failure (New York Heart Association [NYHA] grade ≥ III), and severe arrhythmias (including QTc interphase > 480 ms, corrected by Fridericia formula), uncontrolled hypertension (systolic ≥ 160 mmHg or diastolic ≥100 mmHg), deep vein thrombosis, etc.
  18. Study patients who had used emesezumab within 6 months prior to first administration of the drug;
  19. Patients who had used monoclonal antibody therapy, Fc fusion protein products (except FRSW107 and FRSW117), PEG products (except FRSW117), or intravenous immunoglobulin infusion within 3 months before the first administration of the investigational drug;
  20. Study patients who underwent major surgery within 3 months prior to initial drug administration (major surgery is defined in 6.2.3 Perioperative management);
  21. Study patients who have used FⅧ preparation of any standard half-life (e.g., Bycoch, Coproch, Biinidin, Renjie, NoL, Antaine, etc.) within 3 days or 5 half-lives prior to first administration of the drug (taking the elderly); Patients who have used any other extended half-life preparation FⅧ within 4 days or 5 half-lives prior to first dosing (for the elderly);
  22. Study patients with fever, severe active bacterial or viral infection, and allergies within 2 weeks before the first administration of the drug;
  23. Systemic immunomodulators (such as glucocorticoids [> 10 mg/ day equivalent dose of prednisone], alpha-interferon, immunoglobulin, cyclophosphamide, cyclosporin, etc.) used within 14 days prior to the first administration of the study drug or planned during the study period were allowed to be inhaled, nasal spray, or topical corticosteroids;
  24. Those who had been vaccinated within 4 weeks prior to initial administration of the study drug; Or who plan to be vaccinated during PK blood collection (only for subjects in the PK subgroup);
  25. Plan to have a child or sperm donation during the entire trial period and within 3 months after the last dose, or do not want to use effective physical contraception (such as condoms, diaphragms, Iuds, etc.);
  26. Have other serious medical conditions that the researchers said could not benefit from them
  27. Subjects deemed unsuitable by other investigators.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: N/A
  • Intervenční model: Přiřazení jedné skupiny
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: On-demand Treatment.
On-demand treatment (recommended range: 20-50 IU/kg)
Treatment for 6 months as needed.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
The haemostatic effective rate
Časové okno: 6 months
The haemostatic effect of FRSW107 when used for treatment of bleeds, assessed on a four-point scale for haemostatic response (excellent, good, moderate and none) by counting excellent and good as success and moderate and none as failure.
6 months

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Number of infusions and IU/kg of FRSW107 needed for the treatment of bleeding episodes
Časové okno: 6 months
6 months
FVIII activity during on-demand: activity recovery rate
Časové okno: Visit1,Day1
FVIII activity recovery rate on Day1's haemostatic therapy.
Visit1,Day1
Hemophilia Joint Health Score (HJHS 2.1) during on-demand treatment
Časové okno: 6 month
total score and each subscale score of HJHS 2.1, as well as their changes over time.
6 month
incidence of lack of drug efficacy
Časové okno: 6 months

Lack of drug efficacy is defined as: during on-demand treatment, hemostatic efficacy is assessed as "ineffective" or "poor/no response" following two consecutive administrations within 72 hours for the same bleeding episode.

incidence of lack of drug efficacy=number of lack of drug efficacy/number of evaluated treatment*100%.

6 months
Occurrence of AEs and SAEs
Časové okno: 6 month
6 month
Incidence rate of positive FVIII inhibitors
Časové okno: 6 month
A positive FⅧ inhibitor is defined as a Bethesda inhibitor titer ≥ 0.6 BU/mL. Incidence rate of positive FVIII inhibitors=number of positive FⅧ inhibitors participant / total number of trial participants *100%.
6 month
Incidence rate of positive ADA, Incidence rate of positive anti-CHO antibody
Časové okno: 6 month
Incidence rate of positive ADA=number of positive ADA participant / total number of trial participants *100% Incidence rate of positive anti-CHO antibody=number of positive anti-CHO antibody participant / total number of trial participants *100%
6 month

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Studijní židle: Renchi Yang, PhD, Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

14. dubna 2026

Primární dokončení (Odhadovaný)

1. února 2027

Dokončení studie (Odhadovaný)

1. června 2027

Termíny zápisu do studia

První předloženo

15. června 2026

První předloženo, které splnilo kritéria kontroly kvality

17. června 2026

První zveřejněno (Aktuální)

23. června 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

8. září 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

2. září 2026

Naposledy ověřeno

1. června 2026

Více informací

Termíny související s touto studií

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit